Mode of action of microbial bioactive metabolites

Folia Microbiologica

Volumn 51, Issue 5, 2006, Pages 359-369

  Behal V ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT;

BACTERIAL PHENOMENA AND FUNCTIONS; CHEMISTRY; DRUG EFFECT; HUMAN; MULTIDRUG RESISTANCE; PHYSIOLOGY; PROTEIN SYNTHESIS; REVIEW;

ANTI-BACTERIAL AGENTS; ANTIPARASITIC AGENTS; ANTIVIRAL AGENTS; BACTERIAL PHYSIOLOGY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PROTEIN BIOSYNTHESIS;

BACTERIA (MICROORGANISMS); NEMATODA;

EID: 33751316793     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02931577     Document Type: Review

References (42)

1. AESCHIMANN J.R., DRESSWR L.D., KAATZ G.W., RYBAK M.J.: Effects of NorA inhibitors on in vitro antibacterial activities and post-antibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob.Agents Chemother. 43, 335-340 (1999).
2. BELOVA L., TENSON T., XIONG L., MCNICHOLS P.M., MANKIN A.S.: A novel site of antibiotic action in the ribosome interaction of evernimicin with the large ribosomal subunit. Proc.Nat.Acad.Sci. USA 98, 3726-3731 (2001).
3. +, low-density sickle and normal red cells. Proc.Nat.Acad.Sci.USA 97, 8045-8050 (2000).
4. BROWN M.J.: Mechanism and specificity of action of ribovirin. Antimicrob.Agents Chemother. 15, 747-753 (1979).
5. BURG R.W., MILLER B.M., BAKER E.E., BIRNBAUM J., CURRIER S.A., HARTMAN R., YU-LING K., MONAGLAN R.L., OLSON G., PUTTER I., TUNAC J.B., WELLICK H., STAMPLEY E.O., OIWA R., OMURA S.: Avermectins, new family of potent anthelmintic agents: production organism and fermentation. Antimicrob.Agents Chemother. 15, 361-367 (1979).
6. CHIAO J.S., YIA T.H., MEI B.G., JIN Z.K., GU W.L.: Rifamycin SV and related ansamycins, pp. 477-498 in L.C. Vining, C. Stuttard (Eds): Genetics and Biochemistry of Antibiotic Production. Butterword-Heinemann, Boston 1995.
7. CHOPRA I., ROBERTS M.: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol.Mol.Biol.Rev. 65, 232-260 (2001).
8. ČIKOŠOVÁ M., BLAZSEK M., KUBIŠ M., GAJDOŠÍKOVÁ J., BOROŠOVÁ G.: Biotechnological preparation of the elaiophylin. Folia Microbiol. 49, 731-736 (2004).
9. DEY S., RAMACHANDRA M., PASTAN I., GATTESMAN M.M., AMBUDKAR S.V.: Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc.Nat.Acad.Sci.USA 94, 10594-10599 (1997).
10. EHRLICH J., COFEY G.L., FISCHER M.W., HILLEGAS A.B., KOHBEGER D.I., MACHAMER H.E., RIGHTSEL H.E., ROEGNER F.R.: 6-Diazo-5-oxo-L-norleucine, a new tumor inhibitory substance. Antibiot. Chemother. 6, 487-496 (1956).
11. FARUTANI M., IIDA T., YAMANO S., KAMINO K., MARUYAMA T.: Biochemical and genetic characterization of an FK506-sensitive peptidyl-prolyl cis-trans isomerase from a thermophilic archeon, Methanococcus thermolithotropicus. J.Bacteriol. 180, 388-394 (1998).
12. FENG Z., BARLETTA R.G.: Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserin. Antimicrob.Agents Chemother. 47, 283-291 (2003).
13. FUKUZAVA M., SHEARER G.M.: Effect of cyclosporin A on T cell immunity. I. Dose-dependent suppression of different murine T-helper cell pathways. Eur.J.Immunol. 19, 49-56 (1989).
14. GANOZA M.C., KIEL M.C.: A ribosomal ATPase is a target for hygromycin B inhibition on Eschericia coli ribosomes. Antimicrob. Agents Chemother. 45, 2813-2819 (2001).
15. HANCOCK R.E.W., CHAPLE D.S.: Peptide antibiotics. Antimicrob.Agents Chemother. 43, 1317-1323 (1999).
16. HEEP M., BECK D., BAYERDOERFFER E., LEHN N.: Rifamin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob. Agens Chemother. 43, 1497-1499 (1999).
17. HENGSTLER J.G., HEIMERDINGER C.K., SCHIFFER I.B., GEBHARD S., SEGEMÜLLER J., TANNER B., BOLT H.M., OESCH F.: Dietary topoisomerase II-poisons: contribution of soy products to infant leukemia? EXLI J. 1, 8-14 (2002).
18. HILLARD J.J., GOLDSCHMIDT R.M., LICATA L., BAUM E.Z., BUSH K.: Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob.Agents Chemother. 43, 1693-1699 (1999).
19. HOPPS H.E., WISSEMANN C.L. Jr., HAHN F.E., SMADEL J.E., HO R.: Mode of action of chloramphenicol - IV. J.Bacteriol. 218, 561-567 (1956).
20. JIN S., GORFAJN G., FAIRCLOTH G., SCOTTO W.: Ecteinascidin 743, a transcription-target chemotherapeutic that inhibits MDR1 activation. Proc.Nat.Acad.Sci.USA 97, 6775-6779 (2000).
21. KAGAWA S.-Z., YAMASHITA Y., OCHIAI K., ANDO K., IWASAKI T., TOKIGUSCHI T., NAKANO H.: Terpentecin and UTC4B, new family of topoisomerase II targeting, antitumor antibiotic produced by Streptomyces: producing organism, fermentation and large scale purification. J.Antibiot. 48, 211-216 (1995).
22. KHAN S.I., NIMROD A.S., MEHROPOOYA M., NITISS J.L., WALKER L.A., CLARL A.M.: Antifungal activity of eupolarine and its action on AND topoisomerases. Antimicrob.Agents Chemother. 46, 1785-1792 (2002).
23. 1 complex from bovine heart. Proc.Nat.Acad.Sci.USA 95, 8026-8033 (1998).
24. KOTRA L.P., HADDAD J., MOBSHERY S.: Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob.Agents Chemother. 44, 3249-3256 (2000).
25. LEE, SANG-YONG, HANG-SUB KIM, YOUNG-HO KIM, SANG-BAE HAN, HWAN-MOOK KIM, SOON-DUCK HONG, JUNG-JOON LEE: Immunosuppressive activity of elaiophylins. J.Microbiol.Biotechnol. 7, 272-277 (1997a).
26. LEE, SANG-YONG, SANG-CHUL HA, YOUNG-SOO HONG, SOON-DUCK HONG, JUNG-JOON LEE: Production of elaiophylin by the strain MCY-846 in a submerged culture. J.Microbiol.Biotechnol. 7, 278-281 (1997b).
27. MACNEIL D.J.: Avermectins, pp. 421-442 in L.C. Vining, C. Stuttard (Eds): Genetics and Biochemistry of Antibiotic Production. Butterword-Heinemann, Boston 1995.
28. MURRAY P.R., PFALLER M.A., Rosenthal K.S.: Medical Microbiology, 5th. ed. ASM Press, Washington (DC) 2005.
29. NAGATA K., SONE N., TAMURA T.: Inhibitory activities of lansoprazole against respiration in Helicobacter pylori. Antimicrob.Agents Chemother. 45, 1522-1527 (2001).
30. NOLLER H.F.: Ribosomal RNA and translation. Ann.Rev.Biochem. 60, 191-227 (1991).
31. OGAWA H., YAMASHIDA Y., KATAHIRA R., CHIBA S., IWASAKI T., ASHIZAWA T., NAKANO H.: UCG9, a new antitumor antibiotic produced by Streptomyces. 1. Producing organism, fermentation, isolation and biological activities. J.Antibiot. 51, 261-266 (1998).
32. OMURA S., SASAKI Y., IWAI Y., TAKESHIMA H.: Staurosporin, a potentially important gift from microorganisms. J.Antibiot. 48, 535-545 (1995).
33. PIDDOCK L.V., JIN Y.F., GRIGGS J.: Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus. J.Antimicrob. Chemother. 47, 261-270 (2001).
34. ROHRER S., BERGER-BAECHI B.: FemABX peptidyl transferase: a link between branched-chain cell wall peptide formation and β-lactam resistance in Gram-positive cocci. Antimicrob.Agents Chemother. 47, 837-846 (2003).
35. RUSSELL R.G., GRAVELEY R., COXON F., SKJDT H., DEL POZO E., ELFORD P., MACKENZIE A.: Cyclosporine A. Mode of action and effects on bone and joint tissues. Scand.J.Rheumatol. 95 (Suppl.), 9-18 (1992).
36. SATO N., YUSA K., NAITO M., TSURUO T.: Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem.Biophys.Res.Commun. 173, 1252-1257 (1990).
37. SHIM J.-H., LEE H.-K., CHANG E.-J., CHAE W.-J., HAN D.-J., MORIO T., YANG J.-J., BOTHWELL A., LEE S.-K.: Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction. Proc.Nat.Acad.Sci.USA 99, 10617-10620 (2002).
38. SUZUKI K., NAGAO K., MONNAI Y., YAGI A., UYEDA M.: Topostatin, a novel inhibitor of topoisomerase I and II produced by Thermomonospora alba strain no. 1520. J.Antibiot. 51, 991-998 (1998).
39. SUZUKI K., YAMAIZUMI M., TATEISHI S., MONNAI Y., UYEDA M.: Topostatin, a novel inhibitor of topoisomerases I and II produced by Thermomonspora alba strain no. 1520. III. Inhibitory properties. J.Antibiot. 52, 460-465 (1999).
40. 1, a novel antiherpetic agent produced by Streptomyces microflavus strain no. 2445. II. Biological properties. J.Antibiot. 41, 1035-1039 (1998).
41. VESTER B., DOUTHWAITE S.: Macrolide resistance conferred by base substitution in 23S rRNA. Antimicrob.Agents Chemother. 45, 1-12 (2001).
42. WIJNHOLDS J., MOL C.A.A.M., VAN DEMETER L., DEHAAS M., SCHEFFER G.L., BAAS F., BEIJNEN J.H., SCHEPER R.J., HATSE S., DE CLERCQ E., BALZARINI J., BORST P.: Multidrug-resistance protein 5 is a multispecific anion transporter able to transport nucleotide analogs. Proc.Nat.Acad.Sci.USA 97, 74-76 (2000).